Will pot stock Auscann Group Holdings Ltd light up the ASX today?

Pot stock Auscann Group Holdings Ltd (ASX:AC8) lists on the ASX today. Will it light up the market on day one?

| More on:
a woman

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This morning the shares of medicinal cannabis company Auscann Group Holdings Ltd (ASX: AC8) will hit the ASX boards following a successful reverse takeover of TW Holdings.

AusCann is the latest in a growing number of "pot stocks" that have listed on the ASX in the last 12 months. Other recent listings include Zelda Therapeutics Ltd (ASX: ZLD), MMJ Phytotech Ltd (ASX: MMJ) and Creso Pharma Ltd (ASX: CPH).

What makes AusCann different?

Although it is early days, I have been impressed with what I've seen from AusCann. As well as having an experienced management team, the company has significant ties with the largest North American producer – Canopy Growth Corp.

The CAD$1.2 billion industry leader is not only a major shareholder in AusCann, but it also provides the company with royalty-free access to its expertise and intellectual property in the cultivation, manufacture, and supply of high-quality medicinal cannabis products.

These products will target palliative care symptoms, chemotherapy-induced nausea, treatment-resistant childhood epilepsy, and chronic pain.

The chronic pain market is the one that really caught my eye. That market alone is estimated by the company to be worth around $5.8 billion a year.

Clearly this would be an incredibly lucrative market for the company if it can bring medicinal cannabis to the masses.

The shared expertise that Canopy Growth Corp provides will be integral to making this a reality, as AusCann will have a battle on its hands to convince Australian doctors to prescribe medicinal cannabis ahead of opioids.

But pleasingly Canopy Growth Corp has been there and done that with its clinician education strategy.

AusCann aims to replicate this strategy through the provision of educational material and by bringing in Canadian prescribers and researchers to conduct education seminars.

Should you invest?

If you were ever going to invest in a medicinal cannabis company then AusCann would have to be the one. But at this stage it is definitely a high risk investment and unsuitable for the average investor.

All being well everything will go to plan and AusCann will become Australia's very own Canopy Growth Corp in a few years. But there certainly is a long road ahead for the company until that happens.

Motley Fool contributor James Mickleboro has no position in any stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

More on ⏸️ Investing

Close up of baby looking puzzled
Retail Shares

What has happened to the Baby Bunting (ASX:BBN) share price this year?

It's been a volatile year so far for the Aussie nursery retailer. We take a closer look

Read more »

woman holds sign saying 'we need change' at climate change protest
ETFs

3 ASX ETFs that invest in companies fighting climate change

If you want to shift some of your investments into more ethical companies, exchange-traded funds can offer a good option

Read more »

a jewellery store attendant stands at a cabinet displaying opulent necklaces and earrings featuring diamonds and precious stones.
⏸️ Investing

The Michael Hill (ASX: MHJ) share price poised for growth

Investors will be keeping an eye on the Michael Hill International Limited (ASX: MHJ) share price today. The keen interest…

Read more »

ASX shares buy unstoppable asx share price represented by man in superman cape pointing skyward
⏸️ Investing

The Atomos (ASX:AMS) share price is up 15% in a week

The Atomos (ASX: AMS) share price has surged 15% this week. Let's look at what's ahead as the company build…

Read more »

Two people in suits arm wrestle on a black and white chess board.
Retail Shares

How does the Temple & Webster (ASX:TPW) share price stack up against Nick Scali (ASX:NCK)?

How does the Temple & Webster (ASX: TPW) share price stack up against rival furniture retailer Nick Scali Limited (ASX:…

Read more »

A medical researcher works on a bichip, indicating share price movement in ASX tech companies
Healthcare Shares

The Aroa (ASX:ARX) share price has surged 60% since its IPO

The Aroa (ASX:ARX) share price has surged 60% since the Polynovo (ASX: PNV) competitor listed on the ASX in July.…

Read more »

asx investor daydreaming about US shares
⏸️ How to Invest

How to buy US shares from Australia right now

If you have been wondering how to buy US shares from Australia to gain exposure from the highly topical market,…

Read more »

⏸️ Investing

Why Fox (NASDAQ:FOX) might hurt News Corp (ASX:NWS) shareholders

News Corporation (ASX: NWS) might be facing some existential threats from its American cousins over the riots on 6 January

Read more »